[ OrphoMed raises $39M in Series A ]

OrphoMed has raised $39 million in Series A funding.

Founded in 2015, OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.

The cnew financing will be used to advance the clinical development of OrphoMed’s lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Funding  Series A
Founded  2015
Country  USA
City  Mill Valley, California
Founder / CEO  Nikhilesh Singh
Deal Size  $39M
Investors  New Enterprise Associates
 Takeda Ventures
 Pappas Capital
 Relativity Healthcare Partners
 Mario Family Funds
Previous Investors  /